01177 PE Ratio & Valuation,Is 01177 Overvalued — Intellectia
01177 Relative Valuation
01177's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, 01177 is overvalued; if below, it's undervalued.
Historical Valuation
SINO BIOPHARM(01177) is now in theFairzone, suggesting that its currentforward PEratio of22.71is consideredFairlycompared with the five-year average of20.05.The fair price ofSINO BIOPHARM(01177)is between--to--according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：6.44
Fair
22.71
PE
1Y
3Y
5Y
Trailing
Forward
11.40
EV/EBITDA
SINO BIOPHARM. (01177) has a current EV/EBITDA of 11.40. The 5-year average EV/EBITDA is 10.76. The thresholds are as follows: Strongly Undervalued below 3.58, Undervalued between 3.58 and 7.17, Fairly Valued between 14.34 and 7.17, Overvalued between 14.34 and 17.93, and Strongly Overvalued above 17.93. The current Forward EV/EBITDA of 11.40 falls within the Historic Trend Line -Fairly Valued range.
13.68
EV/EBIT
SINO BIOPHARM. (01177) has a current EV/EBIT of 13.68. The 5-year average EV/EBIT is 13.19. The thresholds are as follows: Strongly Undervalued below 3.32, Undervalued between 3.32 and 8.25, Fairly Valued between 18.13 and 8.25, Overvalued between 18.13 and 23.06, and Strongly Overvalued above 23.06. The current Forward EV/EBIT of 13.68 falls within the Historic Trend Line -Fairly Valued range.
3.02
PS
SINO BIOPHARM. (01177) has a current PS of 3.02. The 5-year average PS is 2.51. The thresholds are as follows: Strongly Undervalued below 0.68, Undervalued between 0.68 and 1.59, Fairly Valued between 3.42 and 1.59, Overvalued between 3.42 and 4.33, and Strongly Overvalued above 4.33. The current Forward PS of 3.02 falls within the Historic Trend Line -Fairly Valued range.
11.83
P/OCF
SINO BIOPHARM. (01177) has a current P/OCF of 11.83. The 5-year average P/OCF is 10.55. The thresholds are as follows: Strongly Undervalued below 4.42, Undervalued between 4.42 and 7.49, Fairly Valued between 13.62 and 7.49, Overvalued between 13.62 and 16.68, and Strongly Overvalued above 16.68. The current Forward P/OCF of 11.83 falls within the Historic Trend Line -Fairly Valued range.
15.80
P/FCF
SINO BIOPHARM. (01177) has a current P/FCF of 15.80. The 5-year average P/FCF is 14.77. The thresholds are as follows: Strongly Undervalued below 5.43, Undervalued between 5.43 and 10.10, Fairly Valued between 19.44 and 10.10, Overvalued between 19.44 and 24.11, and Strongly Overvalued above 24.11. The current Forward P/FCF of 15.80 falls within the Historic Trend Line -Fairly Valued range.
SINO BIOPHARM (01177) has a current Price-to-Book (P/B) ratio of 3.12. Compared to its 3-year average P/B ratio of 2.15 , the current P/B ratio is approximately 45.34% higher. Relative to its 5-year average P/B ratio of 2.85, the current P/B ratio is about 9.67% higher. SINO BIOPHARM (01177) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 7.98%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 6.09% , the current FCF yield is about -100.00% lower.
3.12
P/B
Median3y
2.15
Median5y
2.85
5.62
FCF Yield
Median3y
7.98
Median5y
6.09
Performance Decomposition
1Y
3Y
5Y
Market capitalization of 01177 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 01177 in the past 1 year is driven by Unknown.
Is SINO BIOPHARM (01177) currently overvalued or undervalued?
SINO BIOPHARM(01177)is now in theFairzone, suggesting that its currentforward PEratio of 22.71is consideredFairlycompared with the five-year average of20.05.The fair price of SINO BIOPHARM(01177)is betweentoaccording to relative valuation methord.
What is SINO BIOPHARM (01177) fair value?
01177's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of SINO BIOPHARM (01177) is between to according to relative valuation methord.
How does 01177's valuation metrics compare to the industry average?
The average P/S ratio for 01177's competitors is , providing a benchmark for relative valuation. SINO BIOPHARM Corp (01177) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for SINO BIOPHARM (01177) as of Dec 17 2025?
As of Dec 17 2025, SINO BIOPHARM (01177) has a P/B ratio of 3.12. This indicates that the market values 01177 at 3.12 times its book value.
What is the current FCF Yield for SINO BIOPHARM (01177) as of Dec 17 2025?
As of Dec 17 2025, SINO BIOPHARM (01177) has a FCF Yield of 0.00%. This means that for every dollar of SINO BIOPHARM’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for SINO BIOPHARM (01177) as of Dec 17 2025?
As of Dec 17 2025, SINO BIOPHARM (01177) has a Forward P/E ratio of 22.71. This means the market is willing to pay $22.71 for every dollar of SINO BIOPHARM’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for SINO BIOPHARM (01177) as of Dec 17 2025?
As of Dec 17 2025, SINO BIOPHARM (01177) has a Forward P/S ratio of 0.00. This means the market is valuing 01177 at $0.00 for every dollar of expected revenue over the next 12 months.
